Changelog

All notable changes to OnCo are recorded here. The format follows Keep a Changelog. Dates are release dates; the corpus itself is kept current continuously.

[Unreleased]

Regenerated from the commit log each time the site ships (scripts/changelog-sync.ts); the version sections below are written by hand when a release is cut.

22 September 2026

• fix: use correct filename for Care guide download
• feat: improve Care guide Save and Print functionality
• refactor: simplify Care guide stage filters to plain FilterButtons
• style: American English spelling - ageing→aging, programme→program
• Expand Care guide to 34 articles with improved sorting
• refactor: rename care stages to include stage name and severity
• feat: add downloadable care log PDF to Care guide page
• copy: update Care guide copy to match checkbox UX
• feat: Care guide - add Keep in view checkboxes, Save/Print selection
• feat: add Foundation attribution to footer bottom bar
• refactor: simplify Care guide page - situation cards now filter actions
• feat: update footer with legal bar and Site column
• chore: remove header primary button, keep Care guide in nav array
• chore: remove footer blurb paragraph, keep medical disclaimer
• feat: replace garden plant art with brain-heart brand motif
• fix: replace all brand assets with transparent PNGs (true alpha)
• style: update garden/plant decoration to mint green palette
• UI copy/nav updates: rename Start here, remove homepage search
• Remove 'cited, practical map of dementia' slogan everywhere
• Fix brand mark: use original PNG instead of hand-drawn SVG
• Fix Vercel preview builds: update ignoreCommand
• Replace header logo D mark with brain-in-heart icon
• Replace favicon with mint-green brain-in-heart icon
• Change theme accent from pink to mint green (#3EB489)
• Remove kicker/eyebrow text above homepage hero heading
• Update homepage hero copy with dementia definition
• Add dementia types expansion, First Stages page, and active trials section
• Dementia Atlas: full site polish for families and carers (#2)
• Enable Vercel preview builds for the dementia branch

21 September 2026

• Fix roadmap story colour contrast for axe.
• Harden static export for the dementia-only graph.
• Align CI tests and ask build with tumour-board deletions
• Step 3 Slice A: remove oncology tumour-board tooling
• Land Steps 1-2: dementia-only graph and diagnosis chrome
• Slim CI static export so axe and check can finish
• Fix axe disk usage and dementia graph CI checks
• Point AGENTS.md at the dementia atlas roadmap
• Add dementia atlas agent roadmap
• Fix secret-scan CI by running gitleaks CLI
• Add dementia knowledge graph map and entity seed
• Add Explore nav dropdown and homepage dementia types
• Remove unused legacy UI files
• Fix mobile navigation drawer
• Refine dementia atlas language and navigation
• Port dementia atlas experience
• Refine Dementia Atlas information copy
• Your role, cancer choice and preferences now save to your OnCo account so they follow you across devices, and the outlook block is held back pending a wording review
• Merge cloud profile sync; outlook block held pending wording review
• Add dementia caregiver resources directory
• Community fixes: alphagenome model corrected, epithelioid sarcoma record completed with verified facts, RMC-9805 pancreatic pairing and ubamatamab mechanism corrected, plain-English outlook for ten cancers behind the survival disclosure, and 15 hidden FDA events restored
• Cloud profiles stage one: Supabase tables under the WorkOS token, sync, delete, privacy text
• Add stage-based family guide filters
• PR round 2: alphagenome weights gated, FDA regulatory events surfaced, epithelioid sarcoma withdrawal history
• Preserve link semantics in shared buttons
• Issues 43, 45, 46, 47: prognosis outlook on ten cancer pages, ubamatamab as MUC16xCD3 bispecific with corrected citation, g12d-plus-pan-ras phase and links from the registry and company release
• Add source-linked caregiver playbook
• Roadmap rows 141 and 142: GDPR compliance for accounts and HIPAA readiness
• Label generic therapies and expand verified pipeline
• Add source-linked dementia treatment landscape
• Keep source control utility dependency-free
• Use available GitHub navigation icon
• Restyle Dementia Atlas with knowledge map design
• Fix mobile menu navigation visibility
• Add search-first atlas overview
• Add explore route suspense boundary
• Correct guide timeline syntax
• Fix guide timeline types
• Resolve client state linting
• Build dementia atlas care guide
• chore: render this week's issue to public/newsletter/ (#52)
• chore: refresh public/votes.json from Discussions reactions (#51)
• chore: weekly fact check, audit, and provenance refresh (#50)
• chore: refresh trial counts from ClinicalTrials.gov (#49)

20 September 2026

• Fix duplicate entry for 'alphagenome' in model registry

18 September 2026

• Health data compliance analysis: HIPAA does not apply today, GDPR and state health-data laws do; stay browser-only and prepare encrypted sync
• Top bar sign-in works even before the page script loads: it is now a link that upgrades to the direct WorkOS start
• Top bar button shortened to Sign in/up in every language, and cached pages refreshed so everyone sees the new header
• After sign-in a welcome page asks who you are and which cancer, the top bar shows you are signed in, four community pull requests and four issue fixes land, and secret scanning guards every commit
• Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics
• Welcome step as its own page: sign-in leaves /signup/ for /welcome/ or the return path, signed-in header pill, preferences kept with the account profile
• Secret scanning: gitleaks on every push and pull request, a local pre-commit hook, and an allowlist for public ids and data prose
• Sign up or log in button in the top bar, a medical disclaimer in the footer, and new Terms of Use and Privacy Policy pages
• Trastuzumab carries the June 2026 FDA approval of palbociclib with trastuzumab as HER2-positive maintenance, the one bot proposal from PR 35 not already in the corpus
• Pages are far lighter: the shared header, footer and cancer list are no longer copied into every page's data, and the sign-in id ships with the code
• Terms of use and privacy policy pages, medical disclaimer in the footer, copyright to OnCo
• Header: a Sign up or log in pill when signed out; region, language and search controls sit on the centre line
• Stop serialising the cancer list and the shared chrome into every page's payload
• Sign-in is live: first-time visitors choose whether they are a patient, caregiver, researcher or clinician and can set a cancer, kept only in their browser
• Each ship now builds once: Git-triggered Vercel builds are skipped and only the verified deploy runs
• First sign-in welcome step: who you are, optional cancer, browser-only profile per WorkOS user
• Vercel: skip Git-triggered builds so each ship builds once, from the verified CLI deploy
• add: Strand AI (W26) to the YC oncology list
• Owner list: proposal for six technology sections to lift the section kind past the size gauge
• Every reference DOI on the site checked against Europe PMC: four wrong links corrected, and a checker script added for future waves
• DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added
• Sixty-six landmark and classification papers for the rare-cancer pages, each checked against Europe PMC, plus two corrected reference links
• Initialize project
• Two rare-cancer reference links corrected to the verified POD1UM-303 Lancet 2025 and MEK inhibition Nature 2019 papers
• Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR and ACT II to FIRM-ACT, PATHFINDER, HD21 and FIRSTMAPPP, linked through keyPapers
• Fifth Chinese quality pass over the new rare and pancreatic cancer pages: 14 corrections
• Four pancreatic Chinese TL;DR fixes synced from the wave export into the dictionary
• Chinese TL;DR pass 5: fix 14 rare and pancreatic subtype entries
• Eleven pancreatic cancer pages by stage and driver, from resectable and borderline disease to KRAS G12C, BRCA-mutant and MSI-high tumours, each linked from its trials and drugs
• Add 11 pancreatic cancer subtype pages: stage, driver and histology
• Thirty-nine subtype pages for rarer cancers, from anal and vulvar cancer by HPV status to Hodgkin lymphoma by stage and mastocytosis, plus an IndexNow script for changed pages
• Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adrenocortical, appendiceal, small bowel, cancer of unknown primary, histiocytoses, Langerhans cell histiocytosis, systemic mastocytosis, Hodgkin lymphoma, gestational trophoblastic neoplasia, pheochromocytoma and paraganglioma, nasopharyngeal and sinonasal cancers, with organ-drawing mappings, reverse links from 76 existing trial and drug records, Chinese TL;DRs registered for fold-zh and parent phrases for the cancer-families test
• IndexNow script: submit record pages changed since a date, batched, with a dry run
• Target pages with a mutation hotspot map no longer throw a hydration error: chart tooltips are written as single strings, and the page test now checks markup structure
• Fix hydration error 418 on target pages: multi-child SVG titles rendered empty by the server
• Fourth Chinese quality pass: 22 corrections across researcher, institute, trial and company summaries, including arsenic trioxide and enzalutamide names
• Chinese quality pass 4 over 243 folded TL;DRs
• Thirty-five key papers gain their DOI and PubMed ids, so every key paper but one now shows its citation count
• Add DOIs and PMIDs to 35 key papers that had neither
• Drug cards no longer nest a link inside a link, and a permanent test renders every page to forbid nested anchors site-wide
• Gene targets carry HGNC, Ensembl, UniProt and NCBI Gene identifiers, and key papers show how often they have been cited
• Guard every page against nested anchors; unnest the product card
• Roadmap rows 22 and 97 marked done
• TRACERx 2023 paper DOI corrected (ends -5, verified at doi.org)
• Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets
• Citation counts for key papers from Europe PMC (improvement 97)
• Dependency map hydration error fixed: vendor tiles no longer nest a link inside a link, with a test that forbids nested anchors
• Fix React 418 on the dependency map: no anchor inside an anchor
• Health pass: 369 paper links for 270 researchers, PubChem structures for 43 drugs, six glossary Wikipedia links, refreshed literature snapshots for all 2,093 tracked records, provenance for every record, and 28 logos
• Six more glossary terms gain Wikipedia links; 74 recorded as having no article
• Molecules for 43 more small-molecule and peptide drugs via PubChem name lookup
• Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%
• Trial acronym aliases completed for every registry trial that has one (115 more), so searches by study name find them all
• Add 115 registry trial acronyms from the CT.gov acronym field
• Eighty more drug companies gain Wikipedia and Wikidata links
• Add Wikidata ids and Wikipedia links for 80 more companies
• Sixty-three more institutes and 48 drug companies gain Wikipedia and Wikidata links for readers and machines alike
• Add Wikidata ids and Wikipedia links for 48 companies
• Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API
• Sixty-six hospitals and institutes gain Wikipedia and Wikidata links, which also feed the machine-readable sameAs data for agents
• Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API
• Final researcher identifiers pass: 64 ORCID ids and 60 Wikipedia links, taking 373 people to ORCID and 181 to Wikipedia, plus STRASS trial results
• Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass
• Seventy-seven landmark trials now show their results as structured outcomes transcribed from the published abstracts, and 146 more researchers carry ORCID ids
• Add structured outcomes to STRASS from its Lancet Oncology 2020 abstract
• Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people
• Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts
• A further 121 researchers carry ORCID ids and 18 gain Wikipedia links, each checked against their ORCID employment record
• Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass
• Subtype cancer pages now link their sibling subtypes (667 links) and 188 researchers carry ORCID ids with 22 Wikipedia links
• Add 188 ORCIDs and 22 Wikipedia links to people records
• Forty-one hospitals and institutes added and 78 researchers linked to where they work
• Link cancer subtypes to their siblings and name parents in tldrs
• Fill institutions for 78 trial investigators and add 41 institution records
• Five duplicate person pages merged into one each with redirects, and a duplicate finder for people added
• Merge five duplicate person records and add a duplicate-person finder
• Update weights and URLs for alphagenome model
• A hundred and eleven trial leads and first authors get person pages, linked from the landmark trials and key papers they led, plus 160 more trial acronyms
• A further 160 trial acronyms added as aliases to registry trial records
• Add 111 trial investigators and lead authors named by the subtype trials and key papers
• Trial acronyms (MARIPOSA-2, SPARTAN, CheckMate 9DX and 700 more) added as aliases to registry trial records so searches by the name patients hear find them
• Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases
• Seventeen more landmark trials named on subtype pages (ATTRACTION-2, MAIA, RESONATE-2, NeoSphere and others) recorded with confirmed registry ids, and acronyms added to three registry records
• Third Chinese quality pass: 19 corrections to new drug, company and trial summaries, including wrong drug names and Korean text left in Chinese sentences
• Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled
• Third Chinese quality pass: 19 of 236 TL;DRs from the biomarker, drug, maker and trial waves corrected, and the 73 trial TL;DRs folded into zh.ts
• Seventy-three trials named on subtype pages now have their own records with confirmed registry ids, plus logos for the new drug makers
• Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)

17 September 2026

• Seventy-four drug makers added and 210 drug-to-company links filled, so pipeline drugs now show who is developing them
• Link 193 company-less drugs to their makers and add 74 maker records
• Key papers for 147 subtype pages: 364 pivotal trial, classification and guideline papers, each checked against Europe PMC
• Add key papers to 147 cancer subtype pages
• Thirty-nine drugs named by the new subtype pages now have their own records, from hormone therapies for pituitary tumours to antibody-drug conjugates in trials
• Add drugs named by the cancer subtype pages (drugs-subtypes-wave)
• Fifty biomarker glossary terms named by the new subtype pages (molecular groups, risk scores, resistance mutations), each linked from the pages that use it
• Add 50 biomarker terms named by the cancer subtype pages
• Registry trials linked to 109 subtype pages by driver and stage (1,018 links), with a re-runnable matcher script
• Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens
• Plain-English sentences for the 170 new subtype pages and trials, so every record carries one again
• Add simple sentences for the subtype-wave cancer pages and trials (part-s)
• Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;DRs from tonight's new pages, including one inverted meaning, and adopts NMPA drug names
• Review Chinese TL;DRs of the subtype waves: standard drug names, terms and alignment with the English
• Merge duplicate trial records onto their named keepers
• Head and neck cancers by HPV status and site: HPV-positive and HPV-negative disease, recurrent or metastatic squamous cell carcinoma, hypopharyngeal cancer, three salivary gland histologies and three oral cavity subsites, tied to KEYNOTE-048, RTOG 1016, De-ESCALaTE, ECOG 3311, PATHOS and NIVOPOSTOP
• Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic state page, hypopharyngeal, adenoid cystic, salivary duct, mucoepidermoid, oral tongue, gingivobuccal (India) and lip, with NIVOPOSTOP, ECOG-ACRIN E3311, PATHOS and CAPTAIN-1st
• Neuroendocrine neoplasms by site and grade: small intestinal, pancreatic and lung neuroendocrine tumours, grade 3 NET and extrapulmonary neuroendocrine carcinoma, tied to NETTER-1 and 2, CLARINET, PROMID, RADIANT and CABINET; NETTER-2 refiled under neuroendocrine cancer
• Add neuroendocrine subtypes by site and grade
• Childhood cancers by type and risk: acute lymphoblastic leukaemia by risk group, Philadelphia status, infancy and relapse, paediatric AML, neuroblastoma by risk group, medulloblastoma by molecular group, and a page for adolescents and young adults
• Add paediatric cancers by type and risk group
• Sarcomas and bone tumours by type: chondrosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, alveolar soft part sarcoma, PEComa, epithelioid haemangioendothelioma, nerve sheath tumours, retroperitoneal and extremity soft tissue sarcoma, with STRASS, EORTC 62012, AMPECT and ANGIOTAX
• Add sarcoma and bone tumour subtype pages with landmark trials
• Cancer pages by state for the common cancers: gynaecological cancers by molecular class and stage, skin cancers by state, lung cancer by driver and stage, breast cancer by state, 44 pages tied to their landmark trials and drugs; the My cancer chip leaves the header until accounts are on
• Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive brain metastases, early and metastatic triple-negative, inflammatory breast cancer, Paget disease of the nipple and phyllodes tumour, each linked from the trials and drugs that treat them
• Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials
• Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP
• Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or recurrent endometrial cancer, uterine carcinosarcoma, cervical cancer by stage (early and fertility-sparing, locally advanced, recurrent or metastatic) and ovarian cancer by platinum sensitivity, each tied to its landmark trials and drugs
• Blood cancers by state: acute myeloid leukaemia by driver and fitness, acute promyelocytic leukaemia, myeloma from smouldering to relapsed, MDS by risk, CLL by line and Richter transformation, CML by phase and primary myelofibrosis, nineteen pages tied to 111 drugs and trials
• Blood cancers by driver, state and phase: nineteen subtype pages
• Upper gastrointestinal and liver cancers by state: gastric cancer by HER2, CLDN18.2, PD-L1 and MSI status and early gastric cancer, hepatocellular carcinoma by BCLC stage, intrahepatic and extrahepatic cholangiocarcinoma, and GIST by mutation, each tied to its landmark trials and drugs
• Colorectal cancer by state: rectal, MSI-high, BRAF V600E, HER2-amplified, KRAS G12C and early-onset pages with OPRA, PROSPECT, BEACON and other landmark trials; primary mediastinal B-cell lymphoma
• Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIST by mutation
• Brain tumour subtypes: IDH-mutant astrocytoma, oligodendroglioma, meningioma, brain metastases, paediatric high-grade glioma, spinal cord tumours, vestibular schwannoma and CNS germ cell tumours, each linked from the drugs and trials that treat them
• Add colorectal subtype pages and primary mediastinal B-cell lymphoma
• Add brain and spinal tumour subtype pages
• Plain-English sentences for every remaining record: 1,167 early-phase trials, 138 people, 65 companies, 8 institutions and 3 ideas, so all 11,306 records now carry one
• Simple layer: part-r, fourth and final wave to full coverage
• Websites for 15 organisations and nine more logos, with archived addresses replaced by live sites; roadmap row 139 records the open dependency map hydration mismatch
• Add official websites to 15 sponsor records and fetch nine logos
• Roadmap row 139: dependency map hydration mismatch
• 969 more plain-English sentences for early-phase trials, key papers and collections, taking the simple layer to 9,930 records; one non-cancer registry record removed
• Simple layer wave 3: part-q with 969 sentences (trials, papers, collections)
• Orphan trials given content: ten drug matches, 17 sponsor aliases, 36 sponsor companies and 130 trials tied to their makers, two non-cancer records removed; backlinks round: 303 weakly linked records gain true relations from their own text; orphans down to 214
• After the trial removals: no dangling references, floor re-run, sponsor wave three Chinese folded
• Backlink fill: text-supported relations for 303 weakly connected records
• 1,024 more plain-English sentences: 279 companies, 104 institutions and 640 phase 3 trials, taking the simple layer to 8,961 records
• Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (wave 3); remove two myasthenia gravis records
• Papers for 36 more researchers matched by institution; trial snapshots refreshed for all 1,024 products with 136 registry changes detected; paper snapshots refreshed for all 1,924 records
• Add simple part-p: 1024 plain sentences for companies, institutions, the theories pathway and phase 3 trials
• One papers block per person after the two paper waves met
• People papers: 36 more research-trained people via OpenAlex and Europe PMC
• docs(corrections): name the reporting clinician on the two glioblastoma rows
• Company content and sources for 33 makers, 26 sponsor corrections and papers for twelve researchers; 7,065 reverse links take orphaned trials from 2,467 to 279; Wikipedia links for six terms; structured outcomes with sources for 26 trials; 153 new logos; the schematic gauge counts aliased drawings
• Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge
• Schematic gauge counts aliased drawings as specific
• Add Wikipedia links to six terms lacking one
• Fold a doubled relation line after the sponsor merge
• Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them back; orphan floor 2572 to 384
• Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people
• 661 plain-English sentences: every cancer, 201 drugs, 179 technologies, 120 terms, 50 phase 3 trials and 63 targets; 451 reverse links give 126 orphaned drugs and 105 companies their first inbound link, with three maker corrections
• Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list them back; orphan floor 2827 to 2572
• Simple layer: part-o with 661 sentences, layer test
• Machine translation pipeline for record summaries with hash-checked cache and a report link; 157 Chinese summaries live (every cancer page and nine glossary terms) and two Spanish; model review panel populated for twenty cancers by Fable, each verdict tied to the record's own sources
• Every record has its own RDF Turtle file at /api/v1/rdf/<id>.ttl, linked from the page head, the hidden machine links, JSON-LD, the OpenAPI document and llms.txt
• Machine-translated summaries: cached per record and language under public/i18n/summaries, shown only while the English hash matches, marked as machine translated with a report link and an English toggle; prioritised batch script with a fetch call to the Messages API and a validator for NCT ids, doses, gene symbols and leftover English; hand-written Spanish and Chinese examples for pCR; coverage script counts them
• Per-record RDF: one Turtle file per record at /api/v1/rdf/<id>.ttl, linked from every record page
• For me from a real situation: setting, biomarkers, treatments had, country and trial interest drive what is standard, what your biomarkers change, trials that fit, warnings and questions, all from record fields with sources; dependency map renders identically on server and client
• Theme stays light even when React recovers from a hydration mismatch; the counts grid fills its rows again with twenty kinds
• Fix hydration mismatch on the dependency map
• For me from a real situation (roadmap item 101): setting, biomarkers, treatments had, country and trials drive record-backed sections
• Machines of oncology, second wave: 23 more machine families from boron neutron capture and FLASH beams to hyperthermia, fluorescence surgery, positioning, gating and dosimetry, with 32 vendors; roadmap rows marked done for the day's work
• Decisions you may face: a page per cancer laying out each treatment setting's options, evidence and trade-offs; expert centres as a sortable table of what can be measured, with a near-you marker; your remembered cancer follows you through the header, home, hubs, trials and search; a what-changed page per cancer; red cards for warnings on cancer pages
• Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, endoscopy, skin and cervical imaging, RT guidance and QA, CSTDs
• Prostate cancer by state: eight subtype pages from low risk to neuroendocrine, linked from 45 trials and drugs; Tregzi added from the FDA notice and the remaining update bot proposals checked against the registry; Hansoh merged into one record with a redirect
• Patient roadmap 102, 104, 106: remembered cancer, per-cancer what changed, red cards
• Decision pages per cancer and outcome-based centre tables (roadmap items 107 and 108)
• Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge
• Chinese quality pass: 82 TL;DRs corrected (standard NMPA drug names, basket trial term, methotrexate spelling, idioms), account strings in the formal register
• Radiation wave 5: LET, RBE and when protons beat IMRT
• Chinese quality pass on today's TL;DRs and interface strings: 篮式试验 for basket trial, 甲氨蝶呤 typo, 磁共振直线加速器, established drug names in 61 templated trial lines, natural wording in 30 machine-flavoured sentences, 您 throughout the account strings
• First sixty days after diagnosis: a week-by-week guide for every cancer built from its records, and a printable appointment sheet per cancer with questions, words you may hear and treatments you may be offered
• Model review panel: schema, batch script and page for AI model commentary on records, with two example panels; diagnostics wave two: 24 tests from RAD51 foci and CTC counts to pharmacogenomics, cardiac markers and low-resource screening, with five companies; institution networks: Parker Institute members and leaders, CRUK, NCI, UNICANCER and DKTK links, and ten weakly linked centres strengthened
• Add the first 60 days guide and per-cancer appointment sheets
• Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institution pages
• Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)
• Animations pause off screen, when the tab is hidden and on slow phones, with a shared budget of six spinning molecules or drawings at once; the record page sidebar stays inside its column and never reaches the footer
• Model panel: AI models comment on records beside the human review path
• Search results page as an index: kind chips, did-you-mean, pages strip, Ask OnCo card, related strip; 29 trial design terms and a design picker page; startup requests ranked by urgency and commerciality with every input cited; 51 law and regulation terms by jurisdiction with a law page; translation hygiene: language tags, no-translate on names and doses, a browser translation offer
• Animation budget for slower phones: one hook (use-animation-budget) pauses molecules, wireframe schematics, the docking scene, the garden sway, the body map, the resistance map and the steppers when off screen or the tab is hidden, draws a still frame under reduced motion, caps thumbnails at six spinning per kind, animates on tap on Save-Data or four-core devices, defers structure fetches until on screen, lazy-loads the gallery 3D viewer; record page sidebar confined to its grid column and not sticky when taller than the viewport; roadmap rows 127 and 138
• Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)
• Manufacturing in oncology: seven supply chains, 18 technologies and 14 makers; theories of cancer: a hub map and sixteen theory records with status; platform trials at depth: 21 master protocol trials and a hub term; technology dependency map with 119 edges and a viewer; Chinese TL;DRs folded in for every new record
• Browser translation and language attributes (roadmap row 128, part three): summaries, field values, data tables, bullets and table bodies carry lang="en" while TL;DRs keep their own language; drug, gene, company, trial and person names, aka lines, NCT ids, gene symbols, database ids, molecule labels, formulas and doses carry translate="no" with the notranslate class; TranslateOffer shows one dismissible line at the top of the main column that switches to a carried language or explains the browser's translator in nine languages; wireframe canvas labels repeated as hidden real text; scripts/translation-coverage.ts measures the share of a page in the chosen language per kind
• Rank startup requests by urgency and commerciality (row 112)
• Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)
• Search results page as a proper index (roadmap row 123)
• Manufacturing wave: remove the Hitachi remnant
• Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella trials, STAMPEDE enriched
• Theories of cancer: hub map and sixteen theory records in the mechanics section
• One Hitachi record (machines wave)
• Machines of oncology: 21 machine technologies, 17 vendors and 66 centres with their proton, carbon, MR-linac, Gamma Knife and other rare machines, with a machines page; Free in oncology page with 62 services; tumour sequencing tests compared across 13 laboratories; useful 404 page with nearest matches; section tabs, aligned header icons and unsqueezed tables; machine-readable links, Wikidata sameAs and short titles for search engines and agents; footer credit; navigation starts at the top
• Technology dependency DAG viewer (roadmap 134)
• Manufacturing wave: seven supply chains, 18 technologies, 14 makers
• Merge fixes: single Strata Oncology record, Chinese dictionary without duplicate keys
• Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres
• Free in oncology and tumour sequencing test pages (roadmap 117, 118)
• SEO and agent surface on record pages: titles within 60 chars, Wikidata sameAs, hidden machine-readable landmark
• Compact section tabs, table column widths and header icon alignment
• Make the 404 page useful: nearest matches, ways in, local miss log
• Tables: one shared stand-in for rows with no picture, so no visual slot is ever an empty gap
• Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall through to the profile link; drawer close button without a border; pills never break inside a word; page titles capitalised; landing cards show a corner arrow; off-site links open in a new tab; intoDNA STRIDE and Strata Oncology with sequencing links for testing companies; roadmap rows 115 to 121
• Accounts through WorkOS: browser-only sign-in behind the same account functions, recorded in WorkOS, on when the client id is set; README retitled Total information dominance on cancer with an open-repository note and a screenshot gallery; site title to match; pivot modality headers use one classifier so every header links
• Search index is fresh on every visit (service worker network-first for the API, cache rule narrowed to snapshots and images); site pages ranked higher in search; models table shows each maker's logo or an initials tile; orphan detector script and ratchet test; hub page linked from digital twins
• Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancreatic cancer wave: four failed phase 3 programmes, nimotuzumab's NOTABLE approval, elraglusib, their sponsors and cross-links; PDAC and Cloudflare rows on the roadmap
• Merge PRs 25, 28 and 29 (CheckMate split, topic cards, WebMCP); mobile region menu stays on screen; one heading per cancer group; bevacizumab NICE note; glioblastoma MGMT and tovorafenib wording; mathematical models hub and site pages in search; long lists load in pages as you scroll
• Add progressive WebMCP tools for public oncology search and lookup
• fix: filter cancer topic cards by relevance
• fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6
• Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-long cache headers for snapshots; Cloudflare caching on the roadmap
• Changelog sync keeps the pending entry through the build
• Changelog kept current from the commit log; linked from the README
• Link 51 new technologies back from their drugs, targets and base drawings
• Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers
• Link 28 cancer subtype pages from the drugs and trials that treat them
• Refresh provenance for this week's records
• Cancer links for 20 unlinked trials; Chinese version complete for trials
• Watch button confirms each click
• Country pages: cancer site labels link to their OnCo pages in both tables
• Chinese TL;DRs for the last 87 curated trials and drugs
• Mathematical and biophysical models: 22 model technologies, a third type on the models page
• Types strip as pills, navigator visuals, account-style signup, linked grid headers
• chore: refresh pulse, abstract and citation snapshots (#20)
• chore: refresh institution research output from OpenAlex (#17)
• chore: draft change proposals from feed snapshots

16 September 2026

• Add Anocca; biophysics sources as data-source candidates
• Prevalence rows for 20 more targets
• Prevalence rows for 36 targets
• Molecules for 26 more drugs and tracers
• Molecules for 29 more small-molecule drugs
• Pipelines and missing rows for 29 new cancer pages
• Keep the corpus out of the tool pages' JavaScript
• Keep the corpus out of the guideline pages' JavaScript
• Load translation tables on demand; Chinese TL;DRs for 2,678 registry records
• Chinese TL;DRs for the remaining 131 people
• Subtype pages: leiomyosarcoma, liposarcoma, synovial sarcoma, marginal zone lymphoma, cutaneous T-cell lymphoma
• Subtype pages: kidney, testicular, oesophageal, bladder
• Fix accessibility regressions in shared UI components
• Subtype pages: thyroid, head and neck, ovarian
• Chinese TL;DRs for every company, institution, term and idea
• Radiation wave 4 (21 landmark trials) and Chinese TL;DRs for every cancer, target, technology and curated drug
• Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs
• check-links: separate blocked from broken in the report (#15)
• Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112
• Mobile search opens into the box; radiation wave 1
• Add SciRouter, a prevention-first longevity start-up
• Molecules for 31 small-molecule drugs; gumarontinib folded into glumetinib
• Essential thrombocythaemia page, aspirin record, vorolanib
• Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas
• China deep dive: fifteen trial sponsors as company records
• Offline page only on real failures, China wave 1, favicon set
• Registry trials wave 6 and products wave 7
• Clickable breadcrumbs, pipeline products wave 6, checklist additions
• Header signup, trial wave 5 and Ask weighting
• trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recorded drug and cancer (295 to their sponsor); wave 3 trials gain sponsor links; search lifts the kind named at the start of a question so a 'drug for' query ranks drugs above trials and people
• data: pipeline wave 2 from ClinicalTrials.gov, curated: 27 products missing from the corpus (ten China-approved kinase and checkpoint drugs, Japan's amrubicin and pirarubicin, tabelecleucel, HER2 and GDF-15 antibodies, PSMA and CAIX PET tracers, CD45 radioimmunotherapy and others) with 32 phase 3 trial records and China regional rows; launch checklist gains the agentic and AI accessibility to-do
• cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer, NUT carcinoma) with state of the art, history and development pipelines; six trials (TIGER, SABR-COMET, the tazemetostat run-in, three NUT carcinoma trials) and the BET inhibitor ZEN-3694; gaps page counts only developers as missing products
• site: Google Analytics tag with an honest disclosure on the about page; refresh workflows merge their own pull requests once validate and tests pass (the proposals workflow stays a human gate); deploys the FCCT directory and the nine merged weekly snapshots
• chore: draft change proposals from feed snapshots (#1)
• chore: refresh pulse, abstract and citation snapshots (#2)
• chore: refresh trial counts from ClinicalTrials.gov (#3)
• chore: refresh public/votes.json from Discussions reactions (#5)
• chore: weekly citation link check (#7)
• chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#8)
• chore: refresh preprint tracker from Europe PMC (#9)
• chore: check regional approvals against the EMA register (#10)
• chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#11)
• data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and the FCCT directory brought in: 39 suppliers, tools and services and 10 clinics and centres for tissue preservation, tumour profiling, functional drug testing, liquid biopsy, theranostics, vaccines, cell therapy, trial finding and navigation
• owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton therapy trial and an idea on why ADCs have failed in mesothelioma; cancer pages replace the curated Pipeline list with an In development tab built from the whole corpus; Even One Ventures and fourteen portfolio companies with a weekly-refreshed universe list
• data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indication (historic hormonal and cytotoxic agents, photodynamic and diagnostic agents, growth factors, antiemetics, drugs approved in Japan, China, India or Australia); approval pill no longer wraps
• header: profile icon on every page opens an email capture dialog (magic-link sign-in when accounts are on, list endpoint otherwise); weekly-issue signup boxes removed from footer and newsletter page; strings in nine languages

[1.0.0] - 2026-09-16

Public launch. The site is live at https://onco.cc and the repository is the source of record for the corpus.

Added

• Glossary: twenty canonical categories (mapped at load from the labels written across the data files), one regular category grid with an animation for every category, and a specific picture on every term that has one (its target's schematic, its molecule, its technology's schematic or the organ it concerns) in the table and at the top of the term page.
• Email signup: a SignupBox in the footer and on /newsletter/, driven by NEXT_PUBLIC_SIGNUP_ACTION (Buttondown or Listmonk form endpoint); until it is set the box offers the Atom feed and the per-page Watch button.
• Initials placeholder (RowAvatar) for startups, organisations and people without a usable logo or portrait; hotlinked favicons that fail or come back as the generic 16 px globe fall back to it.
• Journal wordmarks for Nature, the New England Journal of Medicine, Science and The Lancet from Wikidata via their Wikipedia titles, shown on the journals index and journal pages.
• Seventeen ChEMBL drug targets (SRC-family kinases, GM-CSF and IL-11 receptors, xanthine oxidase, DNA polymerase alpha, steroid, serotonin, dopamine, opioid and cannabinoid targets) with HGNC, UniProt and ChEMBL links.
• Six NCI-listed supportive-care drugs (eltrombopag, romiplostim, emapalumab, fostamatinib, ravulizumab, propranolol as Hemangeol) from FDA labels; the chlorambucil-prednisone regimen from the ECOG trial; six earlier Cancer Statistics reports as key papers.
• Papers for sixty-one leaders and OECI representatives via Europe PMC author and affiliation matching, each set checked against the person's role.

Changed

• Provenance tags (gap-fill, chembl-gap, ctgov-ingest, nci-list and similar) are hidden from reader-facing pills and excluded from similarity scoring; they remain in the JSON API.
• People pages show one plain-English provenance line under the papers table instead of a fetcher note on every row.
• Table cells wrap long tokens site-wide; the models table's paper column uses short labels with the identifier as hover text.
• Nine dead organisation websites replaced with verified current addresses; four Wikipedia links repointed to existing articles; every Wikipedia and organisation link in the corpus checked.
• NCI drug list credits two-letter regimen acronyms; the completeness matcher no longer drops "AC".

Also in 1.0.0: work unreleased since 0.4.0

#### Added

• Molecule3D: ball-and-stick models of small molecules (CPK colours, shaded spheres, depth-sorted bond cylinders with double and triple bonds, drag to rotate, element legend) and smooth backbone ribbons for proteins (Catmull-Rom through the C-alpha trace, per-chain colours, wider on helices and strands, bound drug in ball-and-stick), with a wireframe toggle. Used on product pages, in every molecule thumbnail, and in a new "Solved structures with a drug bound" panel on target pages.
• PDB snapshots now keep secondary structure from the HELIX and SHEET records (ss); npm run fetch:structures -- --refresh-pdb 5A9U,5DK3 refreshes chosen entries without touching the rest.
• Startups and investors: company records gain optional stage, ycBatch, investors, funding (sourced rounds, amounts only where the source states them) and acquiredBy; companyType: "investor" for venture funds, corporate venture arms, an accelerator and disease foundations, whose portfolios are derived from backlinks.
• 62 Y Combinator companies attacking cancer, drawn from the open YC directory dataset and checked one by one (src/data/companies-yc.ts, snapshot with every hit and its decision in src/data/universe-lists/yc-oncology.json); 187 further venture-backed oncology companies across therapeutics, diagnostics, AI, digital care, radiotherapy hardware, surgery and tools (src/data/companies-startups.ts); 69 investors (src/data/investors.ts).
• /startups/ (stage strip, YC batch chips, filters by stage, modality, cancer, batch, investor and country, most active investors, recently funded) and /investors/; Funding panel on company pages, Portfolio panel on investor pages; stage and investor facets on /companies/; Startups and Investors in the Institutions & people group.

[0.4.0] - 2026-09-08

Added

• Animated wireframe schematics for all 18 fronts (front pages, Fronts index, home) and for all 19 glossary term categories (/terms/ and every term page).
• Molecule thumbnails wherever a product is mentioned: cards in pipelines, connected lists, and product tabs; hover popover with the rotating molecule on inline drug chips.
• Self-hosted organisation logos under public/logos/ (Wikimedia Commons via Wikidata with domain verification, favicon fallback) for companies, institutions, and collections.
• person kind (clinicians and scientists: role, specialisms, profiles, papers) with a People index and a People tab on institution pages.
• Site favicon and Apple touch icon; GitHub link in the header.
• Public-readiness: CI workflow, issue and pull-request templates, Code of Conduct, security policy, consolidated contributing guide.

Changed

• Graph explorer rebuilt as a clean radial view (fronts inner ring, cancers outer ring) with a focus mode that groups neighbours by kind; no physics.
• Header language and theme controls are single-line and compact.
• Footer and About page carry the work-in-progress disclaimer: verify every fact at its primary source; not medical advice.

[0.3.0] - 2026-09-07

Added

• Deep dives for all 31 cancers (standard of care by setting with NCCN/ESMO guideline mapping, state of the art, history, pipeline, open problems), taking the corpus from 875 to 1574 objects.
• Structured trial outcomes on every trial, out-of-100 pictograms, replication notes, and a disclosed evidence score (/evidence/).
• Product depth: dosing, label-sourced toxicity tables, cost and access, dated regulatory timelines (/regulatory/), class-wise toxicity comparison (/toxicity/), and animated mechanism cards.
• Sourced biomarker prevalence by cancer for targets, with a matrix at /prevalence/.
• Browser-only profile with Navigator (line of therapy, cautions, next options), caregiver mode, and a trial finder with country and distance filters.
• Reading-level and language layers: plain and simple TL;DRs, translations into Spanish, Chinese, Portuguese, and Hindi (machine-assisted, unreviewed), and glossary hovers.
• Power tools: multi-item Compare with differences, Pivot tables, Timeline scrubber, Query builder.
• Trust layer: /audit/ (staleness and contradictions), provenance line per record from the commit history, weekly fact checks against openFDA and ClinicalTrials.gov, confidence chips for ideas and speculative roadmap steps, /corrections/ from CORRECTIONS.md, and expert and patient-advocate review tracks with mandatory conflict-of-interest statements.
• Visuals: pathway diagrams that light up per product, Body map, theme toggle with high contrast and skip link, Story mode on roadmaps, interactive molecule viewer with nine drug–target PDB complexes, animated process schematics (ADC internalisation, CAR-T, radioligand, and more).
• Suggest-an-edit on every page with an organisation self-service track; open evaluation benchmark of 100 questions (/eval/).
• Tabbed object pages with the section kept in the URL; grouped navigation (Find, Map, Intelligence, Who, Learn & contribute) with landing pages.
• Research output ranking from OpenAlex on /universities/, trial leadership index at /leadership/, cooperative trial groups as institution records, funding flows at /funding/, gaps and bounties at /gaps/, annual report at /report/2026/, and an MCP server (npm run mcp).

Changed

• Duplicate entity ids across per-cancer files are merged at load time (first record's scalars win, arrays appended).

[0.2.0] - 2026-09-06

Added

• Slowly rotating 3D wireframes on every product page: small molecules from PubChem 3D conformers, the payload for ADCs, and an IgG C-alpha backbone (PDB 1IGT) for antibodies. Structures are self-hosted under public/structures/.
• Organisation logos on company, institution, and collection pages, hotlinked from the organisation's own site.
• Filterable, sortable products browser at /drugs/ with phase/status, modality, ADC payload class, front, target, cancer, and company facets, in card or table view.
• Explore power view at /explore/: pick a cancer type, switch entity kind, and get a ranked list with a disclosed relevance score.

Changed

• "Sections" renamed to "Fronts" (the fronts of the war on cancer); routes moved from /sections/ to /fronts/.
• Hero line changed to "Total information dominance on cancer."
• The visible "as of" stamp was removed from pages; the internal last-checked date remains in the data for maintainers.

[0.1.0] - 2026-09-04

Added

• Initial release: 642 objects across 14 kinds (cancers, fronts, technologies, targets, products, companies, institutions, pathways, terms, trials, pairings, roadmaps, ideas, collections), one page per object with plain-English TL;DR, derived backlinks, and connected-objects panels.
• Triple-negative breast cancer deep dive (the first fully built example): standard of care by setting, state of the art, history timeline, pipeline, open problems.
• Nine roadmaps including ADC generations, TROP2 ADCs, TNBC, radiopharmaceuticals, cell therapy, molecular imaging, early detection, immunotherapy, and KRAS.
• "For me" cancer picker, institution world map with a disclosed ranking, pathway diagrams, glossary, 50 hub ideas, and a static JSON API at /api/v1/.
• Build-time validation of every cross-reference; MIT code licence, CC BY 4.0 data licence.